Patient demographics and baseline disease characteristics (N = 18 patients)
| Variable | No. of patients (%) |
|---|---|
| Age, years; median (range) | 53 (30–73) |
| Cutaneous primary | 17 (94) |
| Unknown primary | 1 (6) |
| Gender | |
| Female | 12 (67) |
| Male | 6 (33) |
| Performance status (ECOG)a | |
| 0 | 11 (61) |
| 1 | 7 (39) |
| Recurrent disease after prior surgery | 15 (83) |
| Prior adjuvant HDIb | 6 (33) |
| Presence of in-transit metastases | 12 (67) |
| Estimated risk stage | |
| IIIB | 2 (11) |
| IIIC | 16 (89) |
| Tumor mutational status | |
| BRAFV600 | 9 (50) |
| NRASQ61 | 5 (28) |
| Unknown | 1 (5) |
aECOG: Eastern Cooperative Oncology Group; bHDI: high dose interferon-α